Phase 3 N=83 Lifestyle Intervention and Testosterone Replacement in Obese Seniors
Obesity and Hypogonadism
Primary: Change in the Physical Performance Test — 4.6; 4.9 units on a scale — p=0.58
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=40 The Paediatric EVICEL® Soft Tissue and Parenchymal Organ Bleeding Study
Hemorrhage · Soft Tissue Bleeding
Primary: Absolute Time to Haemostasis — 4.0; 4.0 Minutes
Phase 3 N=43 Zevalin-beam for Aggressive Lymphoma
Non-Hodgkin's Lymphoma
Primary: Overall Survival — 91; 62 percentage of participants
Phase 3 N=25 A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa
Hemophilia A With Inhibitors · Hemophilia B With Inhibitors
Primary: Proportion of Successfully Treated Mild/Moderate Bleeding Episodes Per FDA Requirement. — 0.654; 0.603 Proportion of successfully treated BEs
Phase 3 N=205 Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease
Alzheimer Disease
Primary: Risk Ratio for AD Symptom Progression on CDR-SB — 119; 43; 10; 5 Participants — p=0.0313
Phase 3 N=44 An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age
Psoriasis
Primary: Percentage of Participants With Physician's Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 12 — 77.3 percentage of participants
Phase 3 N=340 Prophylactic Ivermectin in COVID-19 Contacts
COVID
Primary: Development of Symptoms ( Fever ,Cough, Sore Throat, Myalgia,Diarrhea, Shortness of Breath) — 15; 59 Participants
Phase 3 N=496 Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
HIV-1 Infection
Primary: Percentage of Participants Who Had HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set — 0.6; 1.8 percentage of…
Phase 3 N=343 A Double-blind Study of Controlled Release OROS Hydromorphone Compared to Placebo in Patients With Chronic Osteoarthritis (OA) Pain
Chronic Pain
Primary: Patient Diary-derived Numeric Rating Scale (NRS) Pain Intensity Change From Baseline to Week 12 or Final Visit of the Double-blind Phase — 0.6; 0.6 units on a scale
Phase 3 N=16 EEG Studies of Ketamine General Anesthesia
Anesthesia
Primary: Average Pain Intensity Pre- and Post-Ketamine Induction — 7.9; 1.6; 4.1; 4.3 score on a scale
Phase 3 N=836 Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis
Anemia · End Stage Renal Disease (ESRD)
Primary: Change From Baseline (BL) to the Average Hemoglobin (Hb) in Weeks 28-36 Without Rescue Therapy [EU (EMA)] — 0.428; 0.193 g/dL — p=<0.001
Phase 3 N=100 TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Disorder With Hyperactivity
Primary: SKAMP (Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale) — -9.1; 5.6 score on a scale — p=<0.0001
Phase 3 N=45 Study of Maca Root for the Treatment of Antidepressant-Induced Sexual Dysfunction in Females
Antidepressant Induced Sexual Dysfunction
Primary: Proportion of Participants in Remission Based on Arizona Sexual Experience Scale (ASEX) Score of 10 or Less After 12 Weeks of Treatment. — 2; 1 participants — p=0.55
Phase 3 N=2,171 An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
Migraine Disorders
Primary: Number of Participants With at Least 1 Treatment Emergent Adverse Event — 447; 545 Participants
Phase 3 N=223 Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects
Alzheimer's Disease
Primary: Confirmatory Phase: Relationship Between Neocortical Flortaucipir Uptake and the Subsequent Rate of Cognitive Decline — 36; 31; 27; 37 Participants — p=0.067